Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
5.65
+0.30 (5.61%)
At close: Jun 6, 2025, 4:00 PM
5.50
-0.15 (-2.65%)
After-hours: Jun 6, 2025, 7:54 PM EDT
Kazia Therapeutics Revenue
In the fiscal year ending June 30, 2024, Kazia Therapeutics had annual revenue of 2.48M AUD with 248,000.00% growth. Kazia Therapeutics had revenue of 2.48M in the half year ending June 30, 2024.
Revenue (ttm)
2.48M AUD
Revenue Growth
+248,000.00%
P/S Ratio
1.80
Revenue / Employee
275,667 AUD
Employees
9
Market Cap
6.32M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 2.48M | 2.48M | 248,000.00% |
Jun 30, 2023 | 1,000.00 | -9.00K | -90.00% |
Jun 30, 2022 | 10.00K | -15.17M | -99.93% |
Jun 30, 2021 | 15.18M | 14.19M | 1,436.54% |
Jun 30, 2020 | 988.11K | -451.89K | -31.38% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KZIA News
- 2 days ago - Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer - PRNewsWire
- 23 days ago - Kazia Therapeutics Highlights Recent Progress and Provides Business Update - PRNewsWire
- 2 months ago - Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil - PRNewsWire
- 4 months ago - Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer - PRNewsWire
- 5 months ago - Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering - PRNewsWire
- 5 months ago - Kazia Therapeutics Announces $2.0 Million Registered Direct Offering - PRNewsWire
- 5 months ago - Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Benzinga
- 5 months ago - Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA - PRNewsWire